Neuropeptide Y modulates steroid production of human adrenal H295R cells through Y1 receptors

Molecular and Cellular Endocrinology

Volumn 314, Issue 1, 2010, Pages 101-109

  Kempna P ^a   Korner M ^b   Waser, B ^b   Hofer, G ^a   Nuoffer, J M ^c   Reubi, J C ^b   Fluck C E ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adrenal; NPY; Steroidogenesis; Tumorigenesis; Y1 receptor

Indexed keywords

3BETA HYDROXY DELTA5 STEROID DEHYDROGENASE; CORTODOXONE; CYTOCHROME P450 1A2; HYDROCORTISONE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; NEUROPEPTIDE Y; NEUROPEPTIDE Y1 RECEPTOR;

ADRENAL CELL; ADRENAL CORTEX; ADRENAL TUMOR; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIGAND BINDING; NERVOUS SYSTEM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; SIGNAL TRANSDUCTION; STEROIDOGENESIS;

ADRENAL GLANDS; ALDOSTERONE; CELL LINE; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; HYDROCORTISONE; HYDROXYSTEROID DEHYDROGENASES; MAP KINASE KINASE KINASES; NEUROPEPTIDE Y; PEPTIDE YY; RADIOIMMUNOASSAY; RECEPTORS, NEUROPEPTIDE Y; SIGNAL TRANSDUCTION; TESTOSTERONE;

EID: 70350196380     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.08.010     Document Type: Article

References (45)

1. Auchus R.J., Lee T.C., and Miller W.L. Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J. Biol. Chem. 273 (1998) 3158-3165
2. Balasubramaniam A. Clinical potentials of neuropeptide Y family of hormones. Am. J. Surg. 183 (2002) 430-434
3. 2+-regulated expression of 21-hydroxylase cytochrome P450 in H295R human adrenocortical cells. J. Clin. Endocrinol. Metab. 83 (1998) 1592-1597
4. Crespo P., Xu N., Simonds W.F., and Gutkind J.S. Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. Nature 369 (1994) 418-420
5. Dardis A., and Miller W.L. Dexamethasone does not exert direct intracellular feedback on steroidgenesis in human adrenal NCI-H295A cells. J. Endocrinol. 179 (2003) 131-142
6. Gazdar A.F., Oie H.K., Shackleton C.H., Chen T.R., Triche T.J., Myers C.E., Chrousos G.P., Brennan M.F., Stein C.A., and La Rocca R.V. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res. 50 (1990) 5488-5496
7. Gudermann T., Grosse R., and Schultz G. Contribution of receptor/G protein signaling to cell growth and transformation. Naunyn Schmiedebergs Arch. Pharmacol. 361 (2000) 345-362
8. Hinson J.P., and Kapas S. Effects of sodium depletion on the response of rat adrenal zona glomerulosa cells to stimulation by neuropeptides: actions of vasoactive intestinal peptide, enkephalin, substance P, neuropeptide Y and corticotrophin-releasing hormone. J. Endocrinol. 146 (1995) 209-214
9. Hinson J.P., Cameron L.A., and Kapas S. Neuropeptide Y modulates the sensitivity of the rat adrenal cortex to stimulation by ACTH. J. Endocrinol. 145 (1995) 283-289
10. Janes M.E., Chu K.M., Clark A.J., and King P.J. Mechanisms of adrenocorticotropin-induced activation of extracellularly regulated kinase 1/2 mitogen-activated protein kinase in the human H295R adrenal cell line. Endocrinology 149 (2008) 1898-1905
11. Kempna P., Hofer G., Mullis P.E., and Fluck C.E. Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. Mol. Pharmacol. 71 (2007) 787-798
12. Kitlinska J., Abe K., Kuo L., Pons J., Yu M., Li L., Tilan J., Everhart L., Lee E.W., Zukowska Z., and Toretsky J.A. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res. 65 (2005) 1719-1728
13. Korner M., and Reubi J.C. NPY receptors in human cancer: a review of current knowledge. Peptides 28 (2007) 419-425
14. Korner M., and Reubi J.C. NPY receptors in primary human brain tumors: over-expression in high grade tumors. J. Neuropathol. Exp. Neurol. 67 (2008) 741-749
15. Korner M., Waser B., and Reubi J.C. High expression of neuropeptide y receptors in tumors of the human adrenal gland and extra-adrenal paraganglia. Clin. Cancer Res. 10 (2004) 8426-8433
16. Korner M., Waser B., and Reubi J.C. Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab. Invest. 84 (2004) 71-80
17. Korner M., Waser B., and Reubi J.C. NPY receptors in human sarcomas: high expression levels of Y1 in Ewing sarcoma family of tumors. Clin. Cancer Res. 14 (2008) 5043-5049
18. Lacroix A., Baldacchino V., Bourdeau I., Hamet P., and Tremblay J. Cushing's syndrome variants secondary to aberrant hormone receptors. Trends Endocrinol. Metab. 15 (2004) 375-382
19. Li Q., Johansson H., and Grimelius L. Innervation of human adrenal gland and adrenal cortical lesions. Virchows Arch. 435 (1999) 580-589
20. Lin D., Harikrishna J.A., Moore C.C.D., Jones K.L., and Miller W.L. Missense mutation serine 106 proline causes 17α-hydroxylase deficiency. J. Biol. Chem. 266 (1991) 15992-15998
21. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) Method. Methods 25 (2001) 402-408
22. Malendowicz L.K., Lesniewska B., and Miskowiak B. Neuropeptide Y inhibits corticosterone secretion by isolated rat adrenocortical cells. Experientia 46 (1990) 721-722
23. Mannon P.J., and Mele J.M. Peptide YY Y1 receptor activates mitogen-activated protein kinase and proliferation in gut epithelial cells via the epidermal growth factor receptor. Biochem. J. 350 Pt 3 (2000) 655-661
24. Mazzuco T.L., Chabre O., Feige J.J., and Thomas M. Aberrant GPCR expression is a sufficient genetic event to trigger adrenocortical tumorigenesis. Mol. Cell. Endocrinol. 265/266 (2007) 23-28
25. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammar D., Quirion R., Schwartz T., and Westfall T. XVI. International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 50 (1998) 143-150
26. Neri G., Andreis P.G., and Nussdorfer G.G. Effects of neuropeptide-Y and substance-P on the secretory activity of dispersed zona-glomerulosa cells of rat adrenal gland. Neuropeptides 17 (1990) 121-125
27. Neri G., Andreis P.G., Malendowicz L.K., and Nussdorfer G.G. Acute action of polypeptide YY (PYY) on rat adrenocortical cells: in vivo versus in vitro effects. Neuropeptides 19 (1991) 73-76
28. Nussdorfer G.G., and Gottardo G. Neuropeptide-Y family of peptides in the autocrine-paracrine regulation of adrenocortical function. Horm. Metab. Res. 30 (1998) 368-373
29. Nussdorfer G.G., Mazzocchi G., and Malendowicz L.K. The possible involvement of pancreatic polypeptide in the paracrine regulation of human and rat adrenal cortex. Endocr. Res. 24 (1998) 695-702
30. Parmar J., Key R.E., and Rainey W.E. Development of an adrenocorticotropin-responsive human adrenocortical carcinoma cell line. J. Clin. Endocrinol. Metab. 93 (2008) 4542-4546
31. Pedrazzini T. Importance of NPY Y1 receptor-mediated pathways: assessment using NPY Y1 receptor knockouts. Neuropeptides 38 (2004) 267-275
32. Pedrazzini T., Pralong F., and Grouzmann E. Neuropeptide Y: the universal soldier. Cell. Mol. Life Sci. 60 (2003) 350-377
33. Rainey W.E., Saner K., and Schimmer B.P. Adrenocortical cell lines. Mol. Cell. Endocrinol. 228 (2004) 23-38
34. Renshaw D., and Hinson J.P. Neuropeptide Y and the adrenal gland: a review. Peptides 22 (2001) 429-438
35. Renshaw D., Thomson L.M., Carroll M., Kapas S., and Hinson J.P. Actions of neuropeptide Y on the rat adrenal cortex. Endocrinology 141 (2000) 169-173
36. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 24 (2003) 389-427
37. Roberge C., Carpentier A.C., Langlois M.F., Baillargeon J.P., Ardilouze J.L., Maheux P., and Gallo-Payet N. Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity. Am. J. Physiol. Endocrinol. Metab. 293 (2007) E1465-1478
38. Rodriguez H., Hum D.W., Staels B., and Miller W.L. Transcription of the human genes for cytochrome P450scc and P450c17 is regulated differently in human adrenal NCI-H295 cells than in mouse adrenal Y1 cells. J. Clin. Endocrinol. Metab. 82 (1997) 365-371
39. Ruscica M., Dozio E., Boghossian S., Bovo G., Martos Riano V., Motta M., and Magni P. Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. Endocrinology 147 (2006) 1466-1473
40. Samandari E., Kempna P., Nuoffer J.M., Hofer G., Mullis P.E., and Fluck C.E. Human adrenal corticocarcinoma NCI-H295R cells produce more androgens than NCI-H295A cells and differ in 3beta-hydroxysteroid dehydrogenase type 2 and 17,20 lyase activities. J. Endocrinol. 195 (2007) 459-472
41. Spinazzi R., Andreis P.G., and Nussdorfer G.G. Neuropeptide-Y and Y-receptors in the autocrine-paracrine regulation of adrenal gland under physiological and pathophysiological conditions (review). Int. J. Mol. Med. 15 (2005) 3-13
42. Stocco D.M., Wang X., Jo Y., and Manna P.R. Multiple signaling pathways regulating steroidogenesis and steroidogenic acute regulatory protein expression: more complicated than we thought. Mol. Endocrinol. 19 (2005) 2647-2659
43. Tee M.K., Dong Q., and Miller W.L. Pathways leading to phosphorylation of P450c17 and to the posttranslational regulation of androgen biosynthesis. Endocrinology 49 (2008) 2667-2677
44. Whitworth E.J., Kosti O., Renshaw D., and Hinson J.P. Adrenal neuropeptides: regulation and interaction with ACTH and other adrenal regulators. Microsc. Res. Tech. 61 (2003) 259-267
45. Ye P., Nakamura Y., Lalli E., and Rainey W.E. Differential effects of high and low steroidogenic factor-1 expression on CYP11B2 expression and aldosterone production in adrenocortical cells. Endocrinology 150 (2009) 1303-1309